Narcolepsy Meeting Focuses on Symptoms, But Some Urge Attention to Underlying Cause

Posted by on Oct 17, 2013 in Awareness

The Pink Sheet, October 7, 2013 Excessive daytime sleepiness, interrupted nighttime sleep and “brain fog” are key symptoms that new drugs developed for the treatment of narcolepsy should target, patients told FDA Sept. 24. During a four-hour meeting held as part of the agency’s patient-focused drug development initiative, dozens of patients and caregivers talked about […]

View the FDA Narcolepsy Hearing Video

Posted by on Oct 4, 2013 in Awareness

Curious about the inner workings of government? This video documents the entire September 24 public meeting of the Food & Drug Administration. FDA officials invited narcolepsy patients and care-givers to share their stories of how the disease affects them, and their perspectives on the effectiveness of current therapies.  Video Part 1 Video Part 2  […]

FDA Hears Narcolepsy Realities from Patients and Caregivers

Posted by on Oct 4, 2013 in Awareness

By K. Kimberly McCleary       The skies above the U.S. Food & Drug Administration’s Silver Spring, Maryland, campus were clear and bright blue, a welcoming sign to nearly 150 narcolepsy patients, family members, and other stakeholders who gathered in the agency’s public facility on September 24, 2013. Many arrived well ahead of the […]